Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B99: Pembrolizumab + Investigational Agents + Chemotherapy in First-Line ES-SCLC
NCT04924101Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 11
01
Overview
A Phase 2 trial of mk-4830, boserolimab, lenvatinib in small cell lung cancer (SCLC), sponsored by Merck & Co.. Started Jul 2021; status: completed.
02
Drugs
mk-4830boserolimablenvatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04924101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04924101.